Recent large clinical studies of high quality have unequivocally proven that SGLT2 inhibition has further significant and diabetes-independent cardio- and nephroprotective effects that are, in many aspects, regarded as a milestone in cardiology and nephrology (38–40). The gene discussed is SLC5A2; the disease is diabetes mellitus.